Citations

Clear

3942 citation(s) found for "To, Van".

Injury differences between youth male and female American football players
Sugimoto, Dai , Tadros, Meena M., Pelt, Robert Van, Radel, Luke C. , Soma, David , Ulman, Sophia , Radel, Luke, Ulman, Sophia , Mikhail, David, Pelt, Bobby Van , Miller, Shane M. , Jones, Jacob C.

Mayo Clinic

The Physician and Sportsmedicine | February 18, 2025 | Volume: 53 | Issue: 4 | Pages: 337-344

10.1080/00913847.2025.2468632 | PMID 39998429 Get It

Direct Reinfusion of Shed Autologous Blood in Major Aortic Repair: An Intriguing Concept But Are We Putting the Cart Before the Horse?
Buskirk, Camille M. van , Klompas, Allan M. , van Buskirk, Camille M, Warner, Matthew A.

Mayo Clinic

Anesthesia & Analgesia | February 18, 2025 | Volume: 140 | Issue: 3 | Pages: 524-526

10.1213/ane.0000000000007174 | PMID 39976618 Get It

Increased Interaction between B Cells and CD3+ T Cells in Nonprogressors with Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma
Bartemes, Kathleen R. , Moore, Raymond M. , Novotny, Brenna C. , Pavelko, Kevin D. , Sherman, William H., Rivera, Michael , García, Joaquín J. , Daniel, J. , Moore, Eric J. , Abel, Kathryn M. Van , Sherman, William , Sherman, Will A , Yin, Linda X , Ma, Daniel , Moore, Eric J , Van Abel, Kathryn M , Routman, David M , Pavelko, Kevin D , Novotny, Brenna , Yin, Linda X. , Routman, David M.

Mayo Clinic

Clinical Cancer Research | February 18, 2025 | Volume: 31 | Issue: 9 | Pages: 1719-1729

10.1158/1078-0432.ccr-24-2425 | PMID 39964349 Get It

Abstract Purpose: Tumor-infiltrating lymphocytes are associated with a decreased risk of recurrence in human papillomavirus–associated oropharyngeal squamous cell carcinoma. The composition and spatial distribution of tumor-infiltrating lymphocytes and tumor-infiltrating immune cells are not well characterized. Experimental Design: Formalin-fixed, paraffin-embedded primary and lymph node (LN) tumor tissues from 10 progressors (cases) and 10 matched nonprogressors (controls) were interrogated by imaging mass cytometry. Immune, stromal, and tumor cells were quantified from selected regions of interest using machine learning. Nearest neighbors, cell–cell interactions, and niche analyses were performed. Results: In primary regions of interest, immune cell, lymphocyte, T cell, CD8+ T cell, and innate cell prevalence was significantly greater in controls. High prevalence of immune cells, lymphocytes, innate cells, and CD4+ T cells in primary tissues was significantly associated with increased time to event (TTE). Although primary and LN prevalence of T cells, CD4+ T cells, CD8+ T cells, macrophages, and tumor cells were significantly correlated, differences in LNs were neither significant nor associated with TTE. Average distances between T cells and the nearest B cells and between lymphocytes and the nearest tumor cells were decreased in control primary tissues. Interactions between B and T cells were less organized in primary tissues from cases. A niche predominantly comprising lymphocytes was associated with longer TTE. Conclusions: In human papillomavirus–associated oropharyngeal squamous cell carcinoma, immune cell subset prevalence in primary tumors differs with outcome and is associated with TTE. Interactions between B cells and both T-cell subsets are associated with longer TTE, underscoring the importance of active intratumoral immune responses in outcomes.
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
Pierson, Sheila K. , Brandstadter, Joshua D. , Torigian, Drew A. , Bagg, Adam , Lechowicz, Mary Jo , Alapat, Daisy , Casper, Corey , Chadburn, Amy , Chandrakasan, Shanmuganathan , Hoffmann, Christian , Oksenhendler, Éric , Bustamante, Mateo Sarmiento , Streetly, Matthew , Zhang, Lu , Srkalović, Gordan , Dispenzieri, Angela , Fosså, Alexander , Hoffmann, Christian , Ide, Makoto , Kurzrock, Razelle , Mukherjee, Sudipto , Nasta, Sunita , Navarro, José-Tomás , Noy, Ariela , Oksenhendler, Eric , Bustamante, Mateo Sarmiento , Shyamsundar, Saishravan , Wong, Raymond S M , Lim, Megan S , Srkalovic, Gordan , van Rhee, Frits , Fajgenbaum, David C , Casper, Corey , Chandrakasan, Shanmuganathan , Dispenzieri, Angela , Fosså, Alexander , Ide, Makoto , Noy, Ariela , Wong, Raymond , Lim, Megan S. , Rhee, Frits van , Fajgenbaum, David C.

Mayo Clinic

Blood Advances | February 14, 2025 | Volume: 9 | Issue: 8 | Pages: 1952-1965

10.1182/bloodadvances.2024014391 | PMID 39951615 Get It

Abstract Castleman disease (CD) describes a group of rare lymphoproliferative disorders that exhibit a wide range of symptomatology and degree of lymphadenopathy, particularly across the 2 forms of CD with unknown etiology, unicentric CD (UCD), and human herpesvirus-8–negative/idiopathic multicentric CD (iMCD). Whereas UCD cases typically present with localized lymphadenopathy and mild symptoms, iMCD involves multicentric lymphadenopathy and cytokine storm–driven symptoms with 3 recognized clinical phenotypes. Increasingly, there are anecdotal reports of cases that do not fit into this framework, but these cases have not been systematically described. Herein, we use the ACCELERATE natural history registry to characterize the spectrum of CD based on disease features, symptomatology, and severity. Our results characterize a cohort of 179 CD cases, which were reviewed and confirmed by an expert panel of clinicians and hematopathologists. We show that patients with CD present on a continuous spectrum of clinical phenotypes, and we describe oligocentric CD (OligoCD), an intermediate phenotype that does not fit the criteria for UCD or iMCD. These cases tend to have “oligocentric” lymphadenopathy (median [interquartile range] regions of lymphadenopathy, 3.0 [2.0-4.0]) in a regional pattern and exhibit a mild clinical phenotype that is more similar to UCD than iMCD. We also show that patients with OligoCD are inconsistently categorized as UCD vs iMCD, highlighting the need for this characterization. Future data collected through ACCELERATE may further elucidate the natural history and risk profile of these patients.
Intraosseous Pseudoprogression vs. Progression and Recurrence of Clival Chordoma after Proton Radiation Therapy: Case Series
Hong, Sukwoo , Mahajan, Anita , Mark, Ian T. , Gompel, Jamie J. Van , Shinya, Yuki , Van Gompel, Jamie J , Mark, Ian , Laack, Nadia N. , Raghunathan, Aditya

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 14, 2025 | Volume: 87 | Issue: 02 | Pages: 173-181

10.1055/a-2538-3865 | PMID 41808979 Get It

Abstract To propose a novel entity of possible intraosseous pseudoprogression in clival chordoma following proton radiation therapy (PRT). A total of 38 consecutive patients who underwent surgical resection followed by PRT for clival chordoma between January 2015 and December 2023 were analyzed retrospectively. Follow-up magnetic resonance imaging (MRI) suggesting recurrence or progression was evaluated for validity. Apparent diffusion coefficient (ADC) and tumor-to-brainstem signal intensity ratio on contrast-enhanced T1-weighted imaging (Rce) were assessed. Pseudoprogression was defined as (1) MRI signs of recurrence or progression with no pathological confirmation despite obtaining a specimen, or (2) MRI signs of recurrence or regression with spontaneous resolution/regression. Of the 11 patients with MRI findings suggestive of recurrence or progression, 3 were diagnosed with recurrence, 5 with progression, and 3 with pseudoprogression. Patients with pseudoprogression were significantly younger than those with progression (p = 0.04), and all were female. The median time to recurrence, progression, and pseudoprogression was 31, 29, and 21 months, respectively. The three pseudoprogression cases were managed with gross-total resection followed by stereotactic radiosurgery, extensive biopsy, and observation, respectively. Although statistical significance was not reached, ADC (p = 0.33) and Rce (p = 0.13) tended to be higher in pseudoprogression cases. After PRT for clival chordoma, intraosseous pseudoprogression should be considered in the differential diagnosis, particularly in relatively young female patients, although the role of ADC and Rce on MRI remains inconclusive. Multidisciplinary teams managing chordomas should take this into account when determining the aggressiveness of treatment in such cases.
Cardiovascular Symposium on Perspectives in Long COVID
Dieter, Robert S., Dieter, Elizabeth G. , Alcázar, Andrew, Tafur, Alfonso , Gerotziafas, Grigoris , Gonzalez-Ochoa, Alejandro J. , Abdesselem, Salem , Biller, José , Kipshidze, N. , Dreden, Patrick Van , Dieter, Raymond A. , Durvasula, Ravi, Fareed, Jawed , Kempaiah, Prakasha , Gerotziafas, Grigoris T , Gonzalez Ochoa, Alejandro , Kipshidze, Nicholas , Guerrini, Marco , Fareed, Jawed , Kempaiah, Prakasha , Singh, Meharvan

Mayo Clinic

Clinical and Applied Thrombosis/Hemostasis | February 13, 2025 | Volume: 31 | Issue: No issue available | Pages: No page available

10.1177/10760296251319963 | PMID 39943820 Get It

Significant progress has been made in treating Coronavirus disease (COVID) – an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An ominous turn in the pandemic is the evolving public health crisis emanating from persistent SARS-CoV-2 infection and its associated long-term impact. Long COVID or post–COVID syndrome describes protean symptoms that persist at least 3 months after the onset of acute illness and last for at least 2 months in individuals with a history of confirmed SARS-CoV-2 infection. Long COVID has become a public health concern. Millions of infected individuals are now facing chronic multi-organ failures, including neuropsychiatric, cardiovascular, pulmonary, and kidney complications. In general, the cause of long COVID syndrome is unclear but factors such as prolonged activation of immune responses, and viral persistence triggering transcription dysregulation of genes associated with normal thrombotic disease may play a role in cardiovascular complications. Although inflammatory biomarkers are reported in other disorders, it remains unclear whether similar biomarkers are associated with cardiovascular manifestations following COVID. Medications such as sulodexide directed at glycocalyx and coagulation have demonstrated benefits for long COVID in smaller studies. Here, we describe the outcomes of the symposium on the underlying cardiovascular mechanisms of the long COVID.
Patient and clinician satisfaction with home parenteral nutrition intestinal failure telemedicine consultations: A survey of clinicians and patients
Sasegbon, Ayodele , Woods, Amy , Vourloitis, Francesca, Barrett, Maria , Cuerda, Cristina , Jeppesen, Palle Bekker , Joly, Francisca , Lamprecht, Georg , Mundi, Manpreet S. , Szczepanek, Kinga , Gossum, A. Van , Vanuytsel, Tim , Wanten, Geert, Lal, Simon , Jeppesen, Palle B , Mundi, Manpreet S , Van Gossum, Andre , Pironi, Loris

Mayo Clinic

Nutrition in Clinical Practice | February 13, 2025 | Volume: 40 | Issue: 5 | Pages: 1125-1138

10.1002/ncp.11280 | PMID 39943703 Get It

Abstract Introduction Despite the widespread use of telemedicine to assess patients with intestinal failure (IF) receiving home parenteral nutrition (HPN), satisfaction with remote consultation methods has not been comprehensively assessed. Here, we assessed patient and clinician attitudes to telephone and video IF consultations. Methods Telemedicine questionnaires were designed and distributed in paper form to patients with IF receiving HPN under the care of a UK national IF reference center and electronically to IF clinicians in Europe, North America, Australia, and New Zealand. Results Seventy‐eight patients (53 women and 25 men) and 110 clinicians agreed to complete the questionnaires. Sixty seven percent of patients who had telephone consultations and 50% of patients who had video consultations were satisfied with their consultations. Forty nine percent and 83% of patients who had telephone and video consultations, respectively, felt they were of the same standard as their face‐to‐face consultations. Despite 60% of clinicians feeling telemedicine training would be useful, 55% of clinicians stated they mostly or always met all of the needs of their patients via telephone consultations, whereas 96% of clinicians felt similarly for video consultations ( P = 0.002). A total of 33% and 57% of clinicians felt telephone and video consultations, respectively, were of the same standard as face‐to‐face consultations ( P = 0.004). Conclusion This study comprehensively assesses attitudes to IF telemedicine consultations. Our data show that a large proportion of patients and clinicians are satisfied with IF telephone and video consultations. However, there is an unmet need amongst clinicians for telemedicine training.
Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
Schuiveling, Mark , Maat, Laurens S. ter, Duin, Isabella A.J. van , Verheijden, Rik J. , Troenokarso, Max F., Elias, Sjoerd G. , Burgers, Femke , Berkmortel, Franchette W.P.J. van den , Boers‐Sonderen, Marye J. , Groot, Jan Willem de, Piersma, Djura , Vreugdenhil, Gerard , Kapiteijn, Ellen , Pluim, Josien P. W. , Veta, Mitko , Ter Maat, Laurens S , Haanen, John B A G , Veldhuis, Wouter B , van Diest, Paul J , Leiner, Tim , Veta, Mitko , Moeskops, Pim , Verhoeff, Joost J.C. , Amsterdam, Wouter A. C. van , Boomsma, Martijn F. , Hospers, Geke A.P. , Westgeest, Hans M. , Labots, Mariëtte , Diest, P. J. van , Jong, Pim A. de , Leiner, Tim , Suijkerbuijk, Karijn P.M.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | February 12, 2025 | Volume: 117 | Issue: 6 | Pages: 1245-1252

10.1093/jnci/djaf039 | PMID 39980388 Get It

Abstract Background The association of body composition with checkpoint inhibitor outcomes in melanoma is a matter of ongoing debate. In this study, we aim to investigate body mass index (BMI) alongside computed tomography (CT)-derived body composition metrics in the largest cohort to date. Methods Patients treated with first-line anti-PD1 ± anti-CTLA4 for advanced melanoma were retrospectively identified from 11 melanoma centers in The Netherlands. From baseline CT scans, 5 body composition metrics were extracted: subcutaneous adipose tissue index, visceral adipose tissue index, skeletal muscle index, density, and gauge. These metrics were correlated in univariable and multivariable Cox proportional hazards analysis with progression-free survival, overall survival, and melanoma-specific survival (PFS, OS, and MSS). Results A total of 1471 eligible patients were included. Median PFS and OS were 9.1 and 38.1 months, respectively. Worse PFS was observed in underweight patients (multivariable hazard ratio [HR] = 1.86, 95% CI = 1.14 to 3.06). Furthermore, prolonged OS was observed in patients with higher skeletal muscle density (multivariable HR = 0.88, 95% CI = 0.81 to 0.97) and gauge (multivariable HR = 0.61, 95% CI = 0.82 to 0.998), whereas higher visceral adipose tissue index was associated with worse OS (multivariable HR = 1.12, 95% CI = 1.04 to 1.22). No association with survival outcomes was found for overweight, obesity, or subcutaneous adipose tissue. Conclusion Our findings suggest that underweight BMI is associated with worse PFS, whereas higher skeletal muscle density and lower visceral adipose tissue index were associated with improved OS. These associations were independent of known prognostic factors, including sex, age, performance status, and extent of disease. No significant association between higher BMI and survival outcomes was observed.
Psychological Distress and Quality of Life in Families With a Germline CDKN2A Pathogenic Variant
Onnekink, Anke , Klatte, Derk C.F. , Hooft, Jeanin E. van , Berg, S. H. van den, Zwaan, S. M. S. van der, Potjer, Thomas P. , Bleiker, Eveline M. A. , Onnekink, A M , Klatte, D C F , van Hooft, Jeanin E , Doorn, Remco van , Hinnen, Chris , Leerdam, Monique E. van

Mayo Clinic

Molecular Genetics & Genomic Medicine | February 12, 2025 | Volume: 13 | Issue: 2 | Pages: No page available

10.1002/mgg3.70045 | PMID 39936490 Get It

ABSTRACTBackgroundIndividuals with a germline CDKN2A pathogenic variant (PV) have an increased lifetime risk of melanoma and pancreatic cancer. It is unknown whether the CDKN2A PV impacts quality of life (QoL). Therefore we aimed to assess QoL and psychological distress in families affected by the PV.MethodsThis cross‐sectional study included confirmed carriers and those with a 50% likelihood of carrying the PV (at‐risk carriers) under cancer surveillance who were invited to complete a one‐time questionnaire. Both confirmed and at‐risk carriers are offered skin surveillance, whereas only confirmed carriers aged 40 years or older can participate in pancreatic surveillance.ResultsIn total, 59/247 (24%) individuals under skin surveillance only (skin surveillance group) and 188/290 (65%) individuals under both skin and pancreatic cancer surveillance (pancreatic surveillance group) responded. In both surveillance groups, health‐related QoL and general distress levels were within the general population norms. However, more than 40% of all study participants reported melanoma‐related distress. Pancreatic cancer‐related distress was experienced by 45% of the pancreatic surveillance group. Determinants of cancer‐related distress were a first‐degree relative with melanoma or pancreatic cancer, increased cancer risk perception, and poor general health perception. Over 80% of the participants felt that the benefits of cancer surveillance outweigh the disadvantages.ConclusionIn conclusion, confirmed and at‐risk carriers of the CDKN2A PV under cancer surveillance experienced similar levels of QoL and general distress compared to the general population. However, cancer‐related worry was substantial in this population. These findings can help identify individuals who may benefit from psychological support.
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)
Pazo-Cid, Roberto , Chandana, Sreenivasa R , Dean, Andrew, Leei, Woo Jin, Goetze, Thorsten Oliver , Paulson, Andrew Scott , Bekaii‐Saab, Tanios , Pant, Shubham , Hubner, Richard , Xiao, Zhimin , Chen, Huanyu , Benzaghou, Fawzi, Bekaii-Saab, Tanios S , Wainberg, Zev A. , Melisi, Davide , Macarulla, Teresa , Fouchardière, Christelle de la , Kišš, Igor , Cutsem, Eric Van , Pant, Shubham , O’Reilly, Eileen M.

Mayo Clinic

Future Oncology | February 12, 2025 | Volume: 21 | Issue: 7 | Pages: 765-774

10.1080/14796694.2025.2458458 | PMID 39935331 Get It